Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | Fresolimumab |
Synonyms | |
Therapy Description |
Fresolimumab (GC1008) is a monoclonal antibody that binds TGFB1, TGFB2, and TGFB3, blocking receptor interaction and signaling, which may inhibit proliferation and metastasis of cancer cells (PMID: 24618589, PMID: 31296256). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
Fresolimumab | GC1008 | TGFB (Pan) Antibody 5 | Fresolimumab (GC1008) is a monoclonal antibody that binds TGFB1, TGFB2, and TGFB3, blocking receptor interaction and signaling, which may inhibit proliferation and metastasis of cancer cells (PMID: 24618589, PMID: 31296256). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT02581787 | Phase Ib/II | Fresolimumab | SABR-ATAC: A Trial of TGF-beta Inhibition and Stereotactic Ablative Radiotherapy for Early Stage Non-small Cell Lung Cancer | Completed | USA | 0 |